Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany.

Braun S, Russo L, Zeidler J, Linder R, Hodgkins P.

Clin Ther. 2013 May;35(5):673-85. doi: 10.1016/j.clinthera.2013.03.017. Epub 2013 Apr 13. Erratum in: Clin Ther. 2016 May;38(5):1254-1258.

PMID:
23587606
2.

Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.

Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

J Manag Care Pharm. 2007 Sep;13(7):561-9.

3.

Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.

Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ.

J Manag Care Pharm. 2012 Nov-Dec;18(9):676-89.

4.

ADHD medication use, adherence, persistence and cost among Texas Medicaid children.

Barner JC, Khoza S, Oladapo A.

Curr Med Res Opin. 2011;27 Suppl 2:13-22. doi: 10.1185/03007995.2011.603303.

PMID:
21973228
5.

[Age- and Gender-specific Costs as Well as Drug Therapies of ADHD Patients].

Klora M, Zeidler J, Lublow D, Linder R, Verheyen F, von der Schulenburg JM.

Gesundheitswesen. 2016 Jul;78(7):e23-9. doi: 10.1055/s-0041-110523. Epub 2015 Dec 22. German.

PMID:
26695543
6.

Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study.

Garbe E, Mikolajczyk RT, Banaschewski T, Petermann U, Petermann F, Kraut AA, Langner I.

J Child Adolesc Psychopharmacol. 2012 Dec;22(6):452-8. doi: 10.1089/cap.2012.0022.

7.

Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.

Hodgkins P, Sasané R, Christensen L, Harley C, Liu F.

Curr Med Res Opin. 2011;27 Suppl 2:53-62. doi: 10.1185/03007995.2011.623158.

PMID:
21973231
8.

Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder.

Aldridge AP, Kroutil LA, Cowell AJ, Reeves DB, Van Brunt DL.

Pharmacoeconomics. 2011 Jul;29(7):621-35. doi: 10.2165/11584590-000000000-00000.

PMID:
21473655
9.

Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate.

Treceño C, Martín Arias LH, Sáinz M, Salado I, García Ortega P, Velasco V, Jimeno N, Escudero A, Velasco A, Carvajal A.

Pharmacoepidemiol Drug Saf. 2012 Apr;21(4):435-41. doi: 10.1002/pds.2348. Epub 2012 Jan 17.

PMID:
22253017
10.
11.

Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective.

Štuhec M, Locatelli I, Švab V.

J Child Adolesc Psychopharmacol. 2015 Apr;25(3):254-9. doi: 10.1089/cap.2014.0071. Epub 2015 Mar 24.

PMID:
25803789
12.

The Brazilian policy of withholding treatment for ADHD is probably increasing health and social costs.

Maia CR, Stella SF, Mattos P, Polanczyk GV, Polanczyk CA, Rohde LA.

Rev Bras Psiquiatr. 2015 Jan-Mar;37(1):67-70. doi: 10.1590/1516-4446-2014-1378. Review.

13.

Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD.

Jensen PS, Garcia JA, Glied S, Crowe M, Foster M, Schlander M, Hinshaw S, Vitiello B, Arnold LE, Elliott G, Hechtman L, Newcorn JH, Pelham WE, Swanson J, Wells K.

Am J Psychiatry. 2005 Sep;162(9):1628-36.

PMID:
16135621
14.

Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.

Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Muriel AC, Frank RG.

Arch Gen Psychiatry. 2005 Apr;62(4):435-41.

15.

Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.

Shyu YC, Lee SY, Yuan SS, Yang CJ, Yang KC, Lee TL, Wang LJ.

Clin Ther. 2016 Mar;38(3):595-602. doi: 10.1016/j.clinthera.2016.01.015. Epub 2016 Feb 10.

PMID:
26874787
16.

Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.

Marchetti A, Magar R, Lau H, Murphy EL, Jensen PS, Conners CK, Findling R, Wineburg E, Carotenuto I, Einarson TR, Iskedjian M.

Clin Ther. 2001 Nov;23(11):1904-21.

PMID:
11768842
17.

Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.

Bhang SY, Hwang JW, Kwak YS, Joung YS, Lee S, Kim B, Sohn SH, Chung US, Yang J, Hong M, Bahn GH, Choi HY, Oh IH, Lee YJ.

J Korean Med Sci. 2016 Aug;31(8):1284-91. doi: 10.3346/jkms.2016.31.8.1284. Epub 2016 Jun 7.

18.

An observational study of pharmacological treatment in primary care of children with ADHD in the United kingdom.

Raman SR, Marshall SW, Gaynes BN, Haynes K, Naftel AJ, Stürmer T.

Psychiatr Serv. 2015 Jun;66(6):617-24. doi: 10.1176/appi.ps.201300148. Epub 2015 Mar 1.

PMID:
25726974
19.

Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.

Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, Hollis C, McCarthy S, Murray M, Planner C, Potts L, Sayal K, Taylor E.

Health Technol Assess. 2009 Oct;13(50):iii-iv, ix-xi, 1-120. doi: 10.3310/hta13490.

20.

Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany.

Lindemann C, Langner I, Kraut AA, Banaschewski T, Schad-Hansjosten T, Petermann U, Petermann F, Schreyer-Mehlhop I, Garbe E, Mikolajczyk RT.

J Child Adolesc Psychopharmacol. 2012 Aug;22(4):307-14. doi: 10.1089/cap.2011.0064. Epub 2012 Aug 2.

PMID:
22856384

Supplemental Content

Support Center